Kornimate/medical-research-clean huggingface dataset:
comparison of left and right transradial approach for cag and pci

Conditions: Coronary Artery Disease; Stable Angina; Unstable Angina; Non-ST Elevation Myocardial Infarction; ST-segment Elevation Myocardial Infarction; Ischemic Heart Disease Without Angina

Summary: this trial will compare the procedural success rate between right and left radial approach in patients undergoing coronary angiography and coronary intervention.

the three operators who are proficient in the left radial approach for coronary angiography and coronary intervention will be assigned to the right radial approach for 3 months (phase 1). after then, these three operators will switch approach site to the left radial for another 3 months (phase 2). procedural success, time of the procedure, use of contrast agent, and fluoroscopic data will be compared between right radial approach (phase 1) group and left radial approach (phase 2).

Eligibility criteria:
inclusion criteria: * subjects undergoing coronary angiography via radial approach * subjects undergoing coronary intervention via radial approach * subjects give written informed consent exclusion criteria: * subjects undergoing procedure(s) other than coronary angiography or intervention * subjects with contraindication of radial approach (i.e, non-palpable radial pulsation, abnormal allen's test, known radial artery tortuosity or occlusion, arteriovenous fistula for dialysis)

Keywords: access site transradial access coronary artery disease learning curve
alveolar ridge preservation following tooth extraction using advanced platelet rich fibrin (a-prf) versus platelet rich fibrin (prf)

Conditions: Alveolar Bone Resorption

Summary: the aim of this study is clinically and radiographically evaluate the use of advance platelet rich fibrin (a-prf) versus platelet rich fibrin (prf) in preservation of alveolar ridge following tooth extraction

systemically healthy patients who have at least one non-restorable tooth in the upper inter-bicuspid region and are not seeking immediate or early implant treatment will be allocated in this study after performing nonsurgical periodontal therapy and preoperative periapical therapy to evaluate and improve the condition of the periodontal tissues. anesthesia will be given then flapless atraumatic extraction using periotomes followed by forceps after luxation. for all groups, the socket will be debrided using curette then * group a, the socket will be filled with a.prf * group b the socket will be filled with prf. * group c no bio-additive will be added. * criss cross horizontal mattress suture will be applied to close the extraction wound. prf and a-prf preparation : 10 ml of blood will be drawn from each patient by vein puncture of the antecubital vein. * plateletr ich fibrin (prf) is 3000 rpm and 10 minutes without addition of anticoagulant * advanced platelet rich fibrin (a-prf) is 1300 rpm and 8 minutes.

Eligibility criteria:
inclusion criteria: * patients with at least one non restorable tooth in upper inter-bicuspid region. * stable periodontal condition with no acute periapical infection. * systematically healthy conditions. * cooperative patients. * intact buccal plate of bone. exclusion criteria: * smokers. * patients seeking immediate or early implants. * pregnant females. * bone diseases. * drugs and diseases that may affect platelet count or function.
therapeutic alliances in alcoholism treatment

Conditions: Alcohol Use Disorders

Summary: this project is studying the role of the therapeutic alliance between the therapist and patient in the outpatient treatment of persons with alcohol use disorders.

this project is studying the role of the therapeutic alliance between the therapist and patient in the outpatient treatment of persons with alcohol use disorders. alliances are assessed over the course of treatment and will be reviewed in the context of posttreatment functioning.

Eligibility criteria:
inclusion criteria: * current alcohol dependence diagnosis * live within commuting distance of treatment program * minimum 6th grade reading level * provide consent exclusion criteria: * presence of current organic mental disorder, schizophrenia, or another psychotic disorder * treatment for an alcohol use disorder in past 12 months

Keywords: alcohol use disorders treatment outpatient therapeutic alliance
neurofeedback therapy for children diagnosed with autism

Conditions: Autism Spectrum Disorder

Summary: this project aims: * to further explore the effectiveness of a novel sonified neurofeedback management therapy for children diagnosed with autism spectrum disorder (asd) * to determine if balance control is different before and after therapy

once the informed consent of a parent or guardian has been secured, each child will be asked to provide informed assent. if the child elects to participate in the research project, he/she is enrolled in the study and assign to one of two groups: active comparator or sham comparator. if possible, his/her ability to maintain balance is then assessed using a standard extended mctsib protocol (standing for 25 seconds on a hard surface/4" tall foam cushion with eyes open/closed and head neutral/turned right/left/flexed or extended) and his/her baseline qeeg are recorded. a series of questionnaires will be administered to the child and/or his/her parents/legal guardian/caretaker. afterward the child will be instructed to wear the prescribed device (either the active comparator (mente autism™) or the sham comparator (a device externally identical to mente autism™, providing binaural beats but not tailor-made neurofeedback binaural beats)) to use at home for 40 minutes a day for 12 weeks. at the end of the 12 weeks treatment period, the child will again be tested as at the beginning of the trial (posturography, qeeg, and questionnaires). at the end of the study, participants in the sham comparator group will be offered the option of receiving the full therapy.

Eligibility criteria:
inclusion criteria: * a clear diagnosis of asd and a high starting delta wave level, as confirmed by the initial qeeg. furthermore, since the therapy is administered via a device requiring to be connected to a computer, tablet or phone with wifi capabilities to work, the following are additional requirement: * iphone 4s or later or all ipads except first generation ipad running os v7 or later, or * computer running windows 7 or later * tablet running android 4.1 or later * internet connection exclusion criteria: * a history of hearing impairment and co-morbidities such as rett-syndrome and if they get low delta wave recordings in frontal lobe with qeeg (part of the baseline testing battery)

Keywords: neurofeedback balance, postural postural equilibrium eeg
lfp sensing from directional leads in the acute clinical setting

Conditions: Parkinson Disease, Idiopathic; Parkinson Disease

Summary: this study plans to learn more about the optimal way to program the medtronic deep brain stimulation system in patients with parkinson's disease.

the investigators will conduct a prospective study in patients with parkinson's disease (pd) implanted with standard of care, subthalamic nucleus (stn) deep brain stimulation (dbs) electrodes, to test whether monopolar sensing of the maximal power in the beta frequency range (in stn) predicts the optimal therapeutic stimulation setting for alleviation of pd motor symptoms. participants in this study will have been implanted with a medtronic dbs system consisting of a percepttm pc neurostimulator (battery) and sensight™ dbs leads (implanted electrodes) with brainsensetm technology. the dbs surgery is a standard of care procedure, and no alteration of the surgical plan will occur for research purposes . the ranked response between the clinical profile (therapeutic benefit and adverse effects) and beta power will be compared for all electrical contacts on the implanted electrode. additional analysis of monopolar sensing compared to differential bipolar sensing, location/distance and volume of neural activation (vna) of optimal contacts identified by beta power or therapeutic window will be estimated with respect to the stn. aim 1- determine whether monopolar sensing of beta power, in the outpatient clinic setting, will predict the optimal therapeutic contact for electrical stimulation of the stn. aim 2 - long term follow up (\>12 months) of the same consented study participants to determine the stability of the beta power to determine the optimal contact for therapeutic stimulation.

Eligibility criteria:
inclusion criteria: parkinson's disease, scheduled to undergo bilateral subthalamic nucleus (stn) deep brain stimulation (dbs) surgery at the university of colorado hospital, chosen to have a medtronic deep brain stimulation system implanted (percept™ battery \& sensight™ electrode). parkinson's disease causes upper extremity bradykinesia (slowness of movement) with a mds-updrs1score of 2 or higher when you are off your pd medications. - exclusion criteria: dementia or other psychological disorders that precludes consent to participate. inability to follow testing procedures as determined by the study doctor. inability to be off medication for study visits. existing implanted deep brain stimulation system or implanted cardiac device. unilateral medtronic dbs system, or programming not occurring at the university of colorado hospital. -
antecubital versus femoral approach for adrenal venous sampling

Conditions: Hyperaldosteronism

Summary: subtype diagnosis is crucial for the treatment of primary aldosteronism (pa), which conducts the appropriate treatment strategy. currently, adrenal venous sampling (avs) serves as the gold standard for subtyping of pa. at present, almost all medical centers use the femoral vein approach for avs, and most studies report that the success rate is 30%-80%. our research team is the first in the world to conduct avs via an antecubital approach. the aim of this study is to compare the success rate and safety of avs via antecubital and femoral approach.

primary aldosteronism (pa) is one of the most common causes of secondary hypertension, and its most common subtypes are aldosterone-producing adenoma and idiopathic hyperaldosteronism, which account for 95% to 98% of pa. subtype diagnosis is crucial for the treatment of primary aldosteronism, which conducts the appropriate treatment strategy. currently, adrenal venous sampling (avs) serves as the gold standard for subtyping of pa. at present, almost all medical centers use the femoral vein approach for avs, and most studies report that the success rate is 30%-80%.how to improve the success rate of avs has been a hot topic in the field of primary aldosteronism. our research team is the first in the world to conduct avs via an antecubital approach. the previous study found that the success rate of avs via this approach can reach to 88.0%, with a low incidence of complications. in this study, patients with primary aldosteronism who meet the indications of avs will be randomly assigned to antecubital approach group and femoral approach group. clinical, laboratory and examination data will be recorded and the success rate and safety of avs via antecubital and femoral approach will be compared.

Eligibility criteria:
inclusion criteria: 1. aged from 18 to 60 with no limits in sex; 2. patients with confirmed primary aldosteronism; 3. patients or their legal representatives sign written informed consent approved by the ethics committee exclusion criteria: 1. severe comorbidity, including stroke, myocardial infarction, heart failure, severe valvular heart disease, liver cirrhosis, and metastatic tumor within the previous 3 months； 2. an estimated glomerular filtration rate \ 176 μmol/l； 3. patients who refuse adrenalectomy; 4. suspected of having an adrenocortical carcinoma; 5. allergy to contrast agent; 6. pregnant, nursing, or planning to become pregnant

Keywords: adrenal venous sampling hyperaldosteronism antecubital approach femoral approach
durvalumab plus chemotherapy in untreated patients with extensive-stage small cell lung cancer

Conditions: Small Cell Lung Carcinoma Extensive Disease

Summary: this is a phase iiib, interventional, single arm, multicentre study to evaluate safety, effectivenees, use of resources and patient reporting outcomes in patients with es-sclc treated with durvalumab in combination with platinum-etoposide as first-line treatment in spain.

this trial will provide an opportunity to further evaluate the safety profile and efficacy of durvalumab + ep in patient population that is reflective of real-world clinical practice, durvalumab will be concurrently administered with first-line chemotherapy (ep) on an every 3 week (q3w) schedule for 4 to 6 cycles, and will continue to be administered as monotherapy post-chemotherapy on an every 4 week (q4w) schedule until confirmed progressive disease (pd) or unacceptable toxicity. prophylactic cranial irradiation (pci) is allowed in patients showing complete or partial responses after the durvalumab + ep combination cycles, at the discretion of the investigator according to their local clinical practice.

Eligibility criteria:
inclusion criteria: * histologically or cytologically documented small cell lung cancer with extensive disease. * patients who had received chemoradiotherapy for ls-sclc and have experienced a treatment-free interval of at least 6 months since last chemotherapy, radiotherapy, or chemoradiotherapy cycle, can be included under investigator criteria. * brain metastases; must be asymptomatic or have been treated at least 2 weeks prior to study treatment and are currently receiving 10 mg/day or less of prednisone or equivalent. * patients must be considered suitable to receive a platinum-based chemotherapy regimen as 1st line treatment for es-sclc. * ecog performance status of 0-2 at enrolment. * no prior exposure to immune-mediated therapy for cancer. * adequate hematologic and organ function. * life expectancy of at least 12 weeks. * body weight \>30 kg. exclusion criteria: * any history of radiotherapy to the chest prior to systemic therapy or planned consolidation chest radiation therapy (except paliative care outside of the chest). * paraneoplastic syndrome of autoimmune nature, requiring systemic treatment or clinical symptomatology suggesting worsening of pns * active infection including tuberculosis, hiv, hepatitis b anc c * active or prior documented autoimmune or inflammatory disorders * uncontrolled intercurrent illness, including but not limited to interstitial lung disease.

Keywords: extensive-stage ici sclc durvalumab
dose-ranging study of pradefovir in patients with compensated hepatitis b

Conditions: Hepatitis B, Chronic

Summary: * compare the safety of four oral doses of pradefovir after 48 weeks of treatment * select the dose of pradefovir for phase 3 studies

* compare the safety of four oral doses of pradefovir after 48 weeks of treatment * compare the antiviral activity of four oral doses of pradefovir to adefovir and dipivoxyl after 48 weeks of treatment * select the dose of pradefovir for phase 3 studies * determine the pharacokinetic profiles of four oral doses of pradefovir

Eligibility criteria:
inclusion criteria: * compensated chronic hbv infection * no prior treatment with adefovir dipivoxil * no interferon or lamivudine treatment for three months prior to enrollment * hbeag positive or negative * hbv dna viral load greater than 500,000 copies per ml * alt between 1.2 and 10 times uln exclusion criteria: * positive hiv, hcv, and/or hdv serology * history of renal tubular necrosis * serum creatinine greater than 2.0 mg/dl * history of organ transplant or use of immunosuppresive drugs * pregnant or breast-feeding females

Keywords: hepatitis b, chronic hepatitis b virus pradefovir mesylate adefovir dipivoxyl
safety and efficacy of chloroquine associated with dehydroepiandrosterone sulphate to treat uncomplicated falciparum malaria

Conditions: Malaria

Summary: this study aims to evaluate the safety and efficacy of a standard chloroquine drug regimen administration supplemented with dehydroepiandrosterone sulfate against drug-resistant malaria.

worldwide progression of plasmodium falciparum chloroquine (cq), amodiaquine and sulfadoxine-pyrimethamine resistance leaves few alternative for the control of malaria, particularly in africa. for some strains of p. falciparum and p. berghei, the resistance to cq and aq is linked to an increase in reduced glutathione (gsh) levels and gsh-related enzyme activity, such as glucose 6-phosphate deshydrogenase (g6pd). the pro-hormone dehydroepiandrosterone sulphate can be used to potentiate the antimalarial action of cq on drug resistant p. falciparum strains, by inhibiting parasite g6pd activity. this hormone has a second advantage: it is metabolised in human into a series of potent immunomodulatory steroids which may be in the causal pathway that allowed the induction of protective immune responses against several infections, included malaria. this first study evaluated the tolerance and efficacy of a standard cq regimen supplemented with dehydroepiandrosterone sulphate for the treatment of drug resistant uncomplicated falciparum malaria.

Eligibility criteria:
inclusion criteria: * signing an informed consent (informed consent was given by legal guardian for children); * age egal or more than 15 years; * fever (axillary temperature egal or more than 37.5 °c and less than 40°c) or a history of fever within the last 24 hours; * no sign suggestive of other febrile illness; * absence of signs of complicated malaria (who criteria); * willingness to participate in follow-up for 14 days * a positive thick blood film for p. falciparum without other detectable infectious microorganisms exclusion criteria: * patients taking glucocorticoids or other immuno-suppressive drugs, or indicating recent antimalarial drug history (verbal questionnaire); * severe malaria; * mixed infections; * women using contraceptives; * pregnant women; * breast-feeding women.

Keywords: malaria plasmodium falciparum chemotherapy chloroquine dehydroepiandrosterone sulphate
anthology hip replacement system - orthopaedic data evolution panel (odep) surveillance study

Conditions: Primary Osteoarthritis; Secondary Osteoarthritis; Avascular Necrosis; Primary Total Hip Replacement (THR)

Summary: this clinical study will verify the clinical and radiographic performance of the prosthesis when used in human subjects over a period of 10 years. all complications will be documented.

the clinical evaluations will be based on standard, functional and pain parameters harris hip score pre-operatively, and at 6 months, 3, 5, 7.5 and 10 years post-operatively. postal oxford questionnaire preoperatively, and yearly thereafter. the objective of this study is to analyse the clinical and radiographic responses and the complication rates for patients undergoing primary total hip arthroplasty using the anthology hip replacement system (anthology hip system).

Eligibility criteria:
inclusion criteria: 1. those presenting with primary or secondary osteoarthritis or avascular necrosis of the femoral head or patients suitable for a primary total hip replacement. this is the patient group that will benefit from operative surgery to treat osteoarthritis. 2. those deemed capable of giving informed consent, understanding the aims of the study and expressing willingness to comply with the post-operative review programme. patients capable of giving informed consent are eligible for inclusion into the study. 3. participants who signed the ethics committee approved specific informed consent form prior to surgery. patients who have not given informed consent will not be eligible for inclusion into the study. exclusion criteria: 1. patients whose prospects for a recovery to independent mobility would be compromised by known coexistent, medical problems. 2. patients not suitable for primary hip replacement. 3. patients with active or suspected infection.

Keywords: thr anthology hip replacement
prevention of colon ischemia during aortic aneurysm (aaa) repair

Conditions: Colon Ischemia; Aortic Aneurysm

Summary: patients undergoing surgery on their aorta can get ischemia, a lack of blood flow, to their intestines and colon. this is very serious, as 2 out of 3 patients who have this problem die before leaving the hospital. a device developed by spectros, called t-stat, is approved by the us fda to detect ischemia, and has been reported to detect ischemia in aaa aneurysm surgery and stenting, allowing the surgeon or interventional radiologist to take action quickly, while the colon ischemia is still treatable. this purpose of this study is to establish how t-stat can best be used to prevent deaths.


Eligibility criteria:
inclusion criteria: * aortic aneurysm, intact or ruptured * repair by catheter based stent or by open surgery during monitoring * patent rectum * absence of rectal bleeding exclusion criteria: * lack of informed consent * rectal bleeding * obstructed rectum

Keywords: tissue oximetry ischemia aortic aneurysm repair aortic stent vascular stent aortic graft vascular graft
music genre stereotypes to boost relaxation in chronic pain patients

Conditions: Anxiety

Summary: social psychological research has demonstrated that internalized stereotypes affect people's attitudes and behaviors. music-based interventions that rely on stereotypes might have promise for keeping participants engaged in health interventions, reducing stress, and improving wellbeing.

group assignments participants will be randomized into one of four groups. 1. group 1 (reggae): participants in this group will receive the stereotype and listen to the music over the 4 weeks. 2. group 2 (preferred): participants in this group will listen to preferred music over the 4 weeks. 3. control group: participants in this group will serve as a control and will not receive any intervention until the study is completed. they will complete a baseline survey and a follow-up survey at four weeks, as well as similar daily surveys. some recordings will be sent to this group after the study is completed, without tracking their usage. intervention all groups will complete a baseline and 4-week follow-up survey. participants in group 1 and group 2 will engage in daily listening 4-week intervention.they will have access to electronic audio recordings, with the order of listening labeled for each day. it is up to them if they want to listen to the daily recordings.

Eligibility criteria:
inclusion criteria: 1. are 18+ 2. live in the us 3. are an english-proficient adult with a chronic pain diagnosis (no restrictions placed on type) 4. have a pain rating of four or greater in average pain on a 0-10 numeric rating scale in the preceding week 5. have had pain for at least 3 months and for at least 15 days in the preceding 30 days 6. have moderate to severe anxiety based on gad-7 exclusion criteria: 1. are currently using or have used prescription opioids in the past 3 months to minimize a known treatment confound and increase sample homogeneity 2. have a current cancer diagnosis